SILVERHAWK-R PERIPHERAL PLAQUE EXCISION SYSTEM FOR SURGICAL USE

K071432 · Fox Hollow Technologies · MCW · Feb 12, 2008 · Cardiovascular

Device Facts

• Record ID: K071432
• Device Name: SILVERHAWK-R PERIPHERAL PLAQUE EXCISION SYSTEM FOR SURGICAL USE
• Applicant: Fox Hollow Technologies
• Product Code: MCW · Cardiovascular
• Decision Date: Feb 12, 2008
• Decision: SESE
• Submission Type: Traditional
• Regulation: 21 CFR 870.4875
• Device Class: Class 2
• Attributes: Therapeutic

Intended Use

The SilverHawk™-R Peripheral Plaque Excision System for Surgical Use is intended for use in atherectomy of the peripheral vasculature. The catheter is not intended for use in the coronary, carotid, iliac or renal vasculature.

Device Story

SilverHawk-R Peripheral Plaque Excision System for Surgical Use consists of a peripheral catheter and a cutter driver. Used for atherectomy of peripheral vasculature; designed to facilitate breakdown of complex, hard, calcified tissue resistant to conventional treatment. Operated by physicians in surgical settings. Device removes plaque via mechanical excision; provides clinicians with ability to excise obstructive tissue. Benefits include improved treatment of calcified peripheral lesions. Provided sterile for single-use.

Clinical Evidence

Bench testing only. Device biocompatibility verified per ISO-10993-1. Sterilization validated per ANSI/AAMI/ISO 11135 (catheter) and ANSI/AAMI/ISO 11137 (cutter driver).

Technological Characteristics

Peripheral atherectomy catheter and cutter driver. Biocompatible materials per ISO-10993-1. Catheter sterilized via Ethylene Oxide (ANSI/AAMI/ISO 11135); cutter driver sterilized via Gamma (ANSI/AAMI/ISO 11137, VDmax method, 25kGy). Single-use.

Indications for Use

Indicated for atherectomy of peripheral vasculature. Not for use in coronary, carotid, iliac, or renal vasculature.

Regulatory Classification

Identification

An intraluminal artery stripper is a device used to perform an endarterectomy (removal of plaque deposits from arterisclerotic arteries.)

Predicate Devices

• SilverHawk Peripheral Plaque Excision System (K061188)

Submission Summary (Full Text)

{0}------------------------------------------------

K071432 \$\beta_{c.j^2}\$ \$l^p\$

# FEB 1 2 2008

Special 510(k)

# 510(K) SUMMARY

#### Device Name

| Classification Name: | Catheter, Peripheral, Atherectomy<br>21 CFR §870.4875, Class II |
|------------------------|----------------------------------------------------------------------|
| Common and Usual Name: | Catheter, Peripheral, Atherectomy |
| Proprietary Name: | SilverHawkTM-R Peripheral Plaque Excision System for<br>Surgical Use |

#### Predicate Device

The SilverHawk Peripheral Plaque Excision System (K061188), currently marketed by FoxHollow Technologies, Inc. (Redwood City, CA).

#### Summary

This summary of Special 510(k) substantial equivalence is being submitted in accordance with requirements of SMDA 1990.

The SilverHawk-R Peripheral Plaque Excision System for Surgical Use is intended for atherectomy of the peripheral vasculature and is not intended for use in the coronary, carotid, iliac or renal vasculature. The SilverHawk-R Peripheral Plaque Excision System for Surqical Use consists of two major components which are packaged separately, but used together during atherectomy procedures. The two components are the SilverHawk-R Peripheral Catheter and SilverHawk Cutter Driver.

The SilverHawk-R Peripheral Plaque Excision System for Surgical Use is provided sterile for single-use. The catheter is sterilized by Ethylene Oxide (ANSI/AAMI/ISO 11135), including limits for Ethylene Oxide residuals and validated to a sterility assurance level (SAL) of 106. The cutter driver is sterilized by Gamma Sterilization Cycle (ANSI/AAMI/ISO 11137), providing a minimum SAL of 108, with a minimum dose of 25kGy, using the VDmax method. The device is biocompatible per ISO-10993-1.

The SilverHawk-R Peripheral Plaque Excision System for Surgical Use is substantially equivalent in material of construction, overall design, indication for use, and safety and efficacy to the predicate device. The subject device was shown to have substantially equivalent performance when compared to the predicate device.

The SilverHawk-R Peripheral Plaque Excision System for Surgical Use with the proposed modifications to facilitate the break down of complex, hard, calcified tissue that may be resistant to conventional treatment, is considered substantially equivalent to the SilverHawk Peripheral Plaque Excision System (K061188).

## Contact

Melissa S. Murphy Requlatory Affairs Manager FoxHollow Technologies, Inc. 740 Bay Road Redwood City, CA 94063 Main Tel [phone]

Date

May 22, 2007

CONFIDENTIAL

{1}------------------------------------------------

Image /page/1/Picture/11 description: The image shows the seal of the Department of Health and Human Services (HHS) of the United States. The seal features the department's name in a circular arrangement around a symbol. The symbol consists of a stylized caduceus, which is a traditional symbol of medicine, with a modern, abstract design. The caduceus is composed of three wavy lines that form a stylized human figure.

FEB 1 2 2008

Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

FoxHollow Technologies, Inc. c/o Ms. Melissa Murphy Regulatory Affairs Manager 740 Bay Road Redwood City, CA 94063

Re: K071432

SilverHawk-R Peripheral Plaque Excision System Regulation Number: 21 CFR 870.4875 Regulation Name: Intraluminal Artery Stripper Regulatory Class: Class II (two) Product Code: MCW Dated: February 7, 2008 Received: February 8, 2008

Dear Ms. Murphy:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

{2}------------------------------------------------

Please be adviscd that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Center for Devices and Radiological Health's (CDRH's) Office of Compliance at [phone]. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding postmarket surveillance, please contact CDRH's Office of Surveillance and Biometric's (OSB's) Division of Postmarket Surveillance at 240-276-3474. For questions regarding the reporting of device adverse events (Medical Device Reporting (MDR)), please contact the Division of Surveillance Systems at 240-276-3464. You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number [phone] or [phone] or at its Internet address http://www.fda.gov/cdrh/industry/support/index.html.

Sincerely yours,

Bram D. Zuckerman, M.D.

Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{3}------------------------------------------------

510(k) Number if known: Device Name: SilverHawk™-R Peripheral Plaque Excision System for Surgical Use

## INDICATION FOR USE:

Indications for Use: The SilverHawk™-R Peripheral Plaque Excision System for Surgical Use is intended for use in atherectomy of the peripheral vasculature. The catheter is not intended for use in the coronary, carotid, iliac or renal vasculature.

Prescription Use X (Per 21 CFR 801 Subpart D) AND/OR

Over-the-Counter Use (Per 21 CFR 807 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

B. Bynum

Air Sign-Off

sion of Cardiovascular Devices
510(k) Number K071432

CONFIDENTIAL

Page 14 of 44